Sutro Biopharma Inc (STRO)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
William J. Newell
Employees:
240
310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO, CA 94080
650-392-8412

Sutro Biopharma, Inc. focuses on creating protein therapeutics for cancer and autoimmune disorders. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.

Data derived from most recent annual or quarterly report
Market Cap 209.935 Million Shares Outstanding60.5 Million Avg 30-day Volume 353.369 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.64
Price to Revenue4.9404 Debt to Equity0.0659 EBITDA-140.809 Million
Price to Book Value1.8158 Operating Margin-279.3423 Enterprise Value-100.506 Million
Current Ratio6.138 EPS Growth0.31 Quick Ratio5.984
1 Yr BETA 0.7632 52-week High/Low 8.72 / 3.24 Profit Margin-250.8678
Operating Cash Flow Growth40.5451 Free Cash Flow to Firm (FCFF) TTM 121.237 Million Free Cash Flow to Equity (FCFE) TTM34.399 Million
Altman Z-Score-1.0833
Earnings Report2023-11-14
View SEC Filings from STRO instead.

View recent insider trading info

Sutro Biopharma Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding STRO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding STRO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-09-19 by GERBER HANS-PETER
  • 3: filed on 2023-09-19 by GERBER HANS-PETER
  • 4: filed on 2023-08-29 by SHTYLLA BRUNILDA
  • 4: filed on 2023-08-28 by SHTYLLA BRUNILDA
  • 4: filed on 2023-08-11 by CHUNG JANE
  • 4: filed on 2023-07-13 by VASQUEZ NICKI
  • 4: filed on 2023-06-12 by HUNTER HEIDI
  • 4: filed on 2023-06-12 by WIGGINTON JON MARC
  • 4: filed on 2023-06-12 by LOBACKI JOSEPH M
  • 4: filed on 2023-06-12 by DYBBS MICHAEL

    • Events (8k)

  • 8-K: filed on 2023-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-26:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2023-06-14:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-04-14:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-03-30:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-24:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-20:
    Item 1.01: Entry into a Material Definitive Agreement

    • Proposed Sales (Form 144)

  • 144: filed on 2023-08-25:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    27 Thousand total shares from 2 transactions

    Exercise Derivative Conversion (M)

    18.8 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GERBER HANS-PETER CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2023-09-18 2

    SHTYLLA BRUNILDA CHIEF BUSINESS OFFICER

    • Officer
    		 0 2023-08-28 4

    CHUNG JANE CHIEF COMMERCIAL OFFICER

    • Officer
    		 31,698 2023-08-09 2

    VASQUEZ NICKI CHIEF PORT. STRAT & ALNCE OFCR

    • Officer
    		 24,988 2023-07-12 3

    PETREE DANIEL H

    • Director
    		 22,457 2023-06-27 2

    PANEK JAMES P

    • Director
    		 0 2023-06-08 1

    MATSUI CONNIE

    • Director
    		 0 2023-06-08 1

    FREUND JOHN GORDON

    • Director
    		 0 2023-06-08 1

    LOBACKI JOSEPH M

    • Director
    		 0 2023-06-08 1

    WIGGINTON JON MARC

    • Director
    		 0 2023-06-08 1

    DYBBS MICHAEL

    • Director
    		 0 2023-06-08 1

    HUNTER HEIDI

    • Director
    		 0 2023-06-08 1

    SRINIVASAN VENKATESH CHIEF TECH OP OFFICER

    • Officer
    		 13,503 2023-05-01 2

    HALLAM TREVOR PRES. RSRCH & CF. SCTIFIC OFCR

    • Officer
    		 100,368 2023-04-14 3

    BORGMAN ANNE ELIZABETH CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-03-15 2

    FITZPATRICK LINDA A CHIEF PEOPLE & COMM. OFFICER

    • Officer
    		 63,073 2023-03-03 2

    ALBINI EDWARD C CFO AND SECRETARY

    • Officer
    		 87,693 2023-03-03 3

    NEWELL WILLIAM J CEO

    • Officer
    • Director
    		 281,341 2023-03-03 2

    SHABBIR ANIK CHIEF TECHNICAL OPS. OFFICER

    • Officer
    		 40,827 2023-03-03 2

    SHARP SHALINI

    • Director
    		 18,500 2022-06-06 0

    MOLINA ARTURO MD CHIEF MEDICAL OFFICER

    • Officer
    		 166,236 2022-03-04 0

    JANNEY DANIEL

    • Director
    		 0 2019-06-17 0

    WORSLEY STEPHEN CHIEF BUSINESS OFFICER

    • Officer
    		 0 2019-01-29 0

    MERCK & CO., INC.

    MERCK SHARP & DOHME CORP.

    • 10% Owner
    		 2,723,509 2018-10-01 0

    CELGENE CORP /DE/

    • 10% Owner
    		 No longer subject to file 2018-10-01 0

    ALTA PARTNERS VIII, L.P.

    ALTA PARTNERS MANAGEMENT VIII, LLC

    CHAMPSI FARAH

    JANNEY DANIEL

    NOHRA GUY P

    • Director
    • 10% Owner
    		 No longer subject to file 2018-10-01 0

    SKYLINE VENTURE PARTNERS V LP

    SKYLINE VENTURE MANAGEMENT V, LLC

    KANEKO YASUNORI

    • 10% Owner
    		 1,960,053 2018-10-01 0

    SVLSF V, LLC

    ILSF III, LLC

    INTERNATIONAL LIFE SCIENCES FUND III (GP), L.P.

    INTERNATIONAL LIFE SCIENCES FUND III STRATEGIC PARTNERS, L.P.

    INTERNATIONAL LIFE SCIENCES FUND III CO-INVESTMENT, L.P.

    INTERNATIONAL LIFE SCIENCES FUND III (LP1), L.P.

    SV LIFE SCIENCES FUND V (GP), LP

    SV LIFE SCIENCES FUND V LP

    SV LIFE SCIENCES FUND V STRATEGIC PARTNERS, L.P.

    • 10% Owner
    		 No longer subject to file 2018-09-27 0

    ROSS MICHAEL JAY

    • Director
    • 10% Owner
    		 1,824,542 2018-09-27 0

    LAWLIS V BRYAN

    • Director
    		 2,478 2018-09-26 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    GERBER HANS-PETER - Officer CHIEF SCIENTIFIC OFFICER

    		2023-09-19 16:19:27 -0400 2023-09-18 A 150,000 a 150,000 direct

    GERBER HANS-PETER - Officer CHIEF SCIENTIFIC OFFICER

    		2023-09-19 16:19:27 -0400 2023-09-18 A 175,000 a 175,000 direct

    SHTYLLA BRUNILDA - Officer CHIEF BUSINESS OFFICER

    		2023-08-29 16:40:06 -0400 2023-08-28 S 15,428 $4.71 d 0 direct -2.0619 -6.3918 0.0 1 -9.2784 4

    SHTYLLA BRUNILDA - Officer CHIEF BUSINESS OFFICER

    		2023-08-28 16:18:22 -0400 2023-08-25 S 11,613 $4.59 d 12,928 direct 1.4644 -5.4393 1.4644 2 -7.9498 5

    CHUNG JANE - Officer CHIEF COMMERCIAL OFFICER

    		2023-08-11 16:16:04 -0400 2023-08-09 F 6,483 $4.22 d 31,698 direct -0.4662 7.9254 -23.31 13.0536 13 -23.31 31

    CHUNG JANE - Officer CHIEF COMMERCIAL OFFICER

    		2023-08-11 16:16:04 -0400 2023-08-09 M 18,750 a 38,181 direct -0.4662 7.9254 -23.31 13.0536 13 -23.31 31

    CHUNG JANE - Officer CHIEF COMMERCIAL OFFICER

    		2023-08-11 16:16:04 -0400 2023-08-09 M 18,750 d 37,500 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SUTRO BIOPHARMA INC STRO 2023-09-29 22:15:03 UTC 4.9078 0.4122 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 21:45:04 UTC 4.9078 0.4122 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 21:15:03 UTC 4.9078 0.4122 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 20:45:05 UTC 4.9078 0.4122 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 20:15:04 UTC 4.9078 0.4122 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 19:45:04 UTC 4.9078 0.4122 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 19:15:03 UTC 0.0 0.0 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 18:45:03 UTC 0.0 0.0 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 18:15:03 UTC 0.0 0.0 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 17:45:03 UTC 4.8817 0.4383 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 17:15:04 UTC 4.8817 0.4383 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 16:45:04 UTC 4.8817 0.4383 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 16:15:03 UTC 4.8817 0.4383 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 15:45:04 UTC 4.8817 0.4383 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 15:15:04 UTC 4.8817 0.4383 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 14:45:04 UTC 4.8817 0.4383 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 14:15:04 UTC 4.8817 0.4383 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 13:45:03 UTC 4.8751 0.4449 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 13:15:04 UTC 4.8751 0.4449 2800000
    SUTRO BIOPHARMA INC STRO 2023-09-29 12:45:05 UTC 4.8751 0.4449 2800000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments